Pulmonary vascular disorders in Covid-19 patients [COVID-19]
Research type
Research Study
Full title
Pulmonary vascular disorders in Covid-19 patients
IRAS ID
283311
Contact name
Gerry Coghlan
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Eudract number
2020-000936-23
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study is looking to see how many patients with COVID-19 have disease in their lungs that affect the blood vessels (pulmonary vasculopathy). \n\nThe study will look at three distinct groups of COVID-19 patients: those with disproportionate hypoxaemia (insufficient oxygen in the blood) ; those with thromboembolic (obstruction of a blood vessel by a blood clot ) disease; and those with inflammation of lung tissue (pneumonitis) where there is no evidence of a blood clot (thromboembolism) when a computed tomography pulmonary angiography (CTPA), a type of CT scan, is performed.\n\nThe study will also look at what impact the use of medications know as vasodilators (they open (dilate) blood vessels) have in patients with COVID-19 and evidence of vasculopathy.\n
REC name
South Central - Berkshire Research Ethics Committee
REC reference
20/SC/0229
Date of REC Opinion
5 Jun 2020
REC opinion
Further Information Favourable Opinion